Literature DB >> 1714520

Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

J Y Xu1, M K Gorny, T Palker, S Karwowska, S Zolla-Pazner.   

Abstract

Immunogenic regions of the gp41 transmembrane protein of human immunodeficiency virus type 1 (HIV-1) were previously mapped by examining polyclonal sera from HIV-infected patients and rodent polyclonal and monoclonal antibodies (MAbs) to peptides of gp41. To define the epitopes within these regions to which infected humans respond during the course of infection, the specificity of human MAbs to these regions had to be studied. Using 10 human MAbs identified initially by their reactivity to whole gp41 in HIV-1 lysates, the epitopes within the immunodominant region of gp41 and within a second immunogenic region of gp41 have been mapped. Thus, five MAbs (from five different patients) to the immunodominant domain of gp41 in the vicinity of the cysteines at positions 598 and 604 (hereinafter designated cluster I) reacted with a stretch of 11 amino acids from positions 590 to 600. Four of these five MAbs were reactive with linear epitopes, while one MAb required the conformation conferred by the disulfide bridge between the aforementioned cysteines. Three MAbs to cluster I revealed dissociation constants ranging from 10(-6) to 10(-8) M, depending on the MAb tested and the size of the synthetic or recombinant peptide used in the assay. Five additional MAbs reacted with a second immunogenic region between positions 644 and 663 (designated cluster II). Four of these five MAbs were specific for conformational determinants. Titration of sera from HIV-infected patients showed that there was about 100-fold more antibody to cluster I than to cluster II in patients' sera, confirming the immunodominance of cluster I.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714520      PMCID: PMC248941     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  A general model for the transmembrane proteins of HIV and other retroviruses.

Authors:  W R Gallaher; J M Ball; R F Garry; M C Griffin; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

2.  Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus.

Authors:  B Banapour; K Rosenthal; L Rabin; V Sharma; L Young; J Fernandez; E Engleman; M McGrath; G Reyes; J Lifson
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

3.  Antibodies against a peptide sequence within the HIV envelope protein crossreacts with human interleukin-2.

Authors:  K L Bost; D W Pascual
Journal:  Immunol Invest       Date:  1988 Aug-Oct       Impact factor: 3.657

4.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

Authors:  M S Reitz; C Wilson; C Naugle; R C Gallo; M Robert-Guroff
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

5.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

Authors:  F Barin; M F McLane; J S Allan; T H Lee; J E Groopman; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

6.  Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe.

Authors:  J Goudsmit; R H Meloen; R Brasseur
Journal:  Intervirology       Date:  1990       Impact factor: 1.763

7.  Highly immunoreactive antigenic site in a hydrophobic domain of HIV-1 gp41 which remains undetectable with conventional immunochemical methods.

Authors:  A Närvänen; M Korkolainen; S Kontio; J Suni; S Turtianen; P Partanen; J Soos; A Vaheri; M L Huhtala
Journal:  AIDS       Date:  1988-04       Impact factor: 4.177

8.  Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.

Authors:  P J Klasse; R Pipkorn; J Blomberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus.

Authors:  J W Gnann; P L Schwimmbeck; J A Nelson; A B Truax; M B Oldstone
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

10.  Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome.

Authors:  H Golding; F A Robey; F T Gates; W Linder; P R Beining; T Hoffman; B Golding
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  135 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection.

Authors:  J Dorn; S Masciotra; C Yang; R Downing; B Biryahwaho; T D Mastro; J Nkengasong; D Pieniazek; M A Rayfield; D J Hu; R B Lal
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 4.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

10.  Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.

Authors:  Z Prohászka; T Hidvégi; E Ujhelyi; H Stoiber; M P Dierich; C Süsal; G Füst
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.